US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
WO1998045331A2
(en)
|
1997-04-07 |
1998-10-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
IL132239A0
(en)
*
|
1997-04-07 |
2001-03-19 |
Genentech Inc |
Humanized antibodies and methods for forming humanized antibodies
|
US7365166B2
(en)
|
1997-04-07 |
2008-04-29 |
Genentech, Inc. |
Anti-VEGF antibodies
|
DK1064382T3
(da)
|
1998-03-17 |
2008-12-08 |
Genentech Inc |
Homologe polypeptider til VEGF og BMP1
|
WO2000029584A1
(en)
|
1998-11-18 |
2000-05-25 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
EP1185559A2
(en)
|
1999-04-28 |
2002-03-13 |
Board Of Regents, The University Of Texas System |
Compositions and methods for cancer treatment by selectively inhibiting vegf
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
US6346249B1
(en)
*
|
1999-10-22 |
2002-02-12 |
Ludwig Institute For Cancer Research |
Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
|
DK1283214T3
(da)
|
2000-04-21 |
2007-06-11 |
Fuso Pharmaceutical Ind |
Hidtil ukendte kollektiner
|
EP2075253A1
(en)
|
2000-06-23 |
2009-07-01 |
Genentech, Inc. |
Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
|
EP2792747A1
(en)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2003216250A1
(en)
*
|
2002-02-11 |
2003-09-04 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
EP1551453A4
(en)
|
2002-06-17 |
2007-04-25 |
Us Gov Health & Human Serv |
SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME
|
AU2004205684A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
CN1829741A
(zh)
|
2003-05-30 |
2006-09-06 |
健泰科生物技术公司 |
利用抗-vegf抗体的治疗
|
CA2537055A1
(en)
*
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
EP2275534A1
(fr)
|
2003-12-02 |
2011-01-19 |
Institut Pasteur |
Nouvelle souche de coronavirus associé au SRAS et ses applications
|
EP2168986A3
(en)
|
2004-02-19 |
2010-07-28 |
Genentech, Inc. |
CDR-repaired antibodies
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
NZ552956A
(en)
|
2004-07-20 |
2010-03-26 |
Genentech Inc |
Inhibitors of angiopoietin-like 4 protein (ANGPTL4), combinations, and their use for treating cancer
|
DK1802334T3
(da)
|
2004-10-21 |
2012-10-15 |
Genentech Inc |
Fremgangsmåde til behandling af intraokulære, neovaskulære sygdomme
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
AU2007248444B2
(en)
|
2006-01-05 |
2012-10-25 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
AR059096A1
(es)
|
2006-01-20 |
2008-03-12 |
Genentech Inc |
Anticuerpos anti- efrina -b2 y metodos que usan estos
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
CA2652733C
(en)
*
|
2006-05-25 |
2016-06-21 |
Glaxo Group Limited |
Modified humanised anti-interleukin-18 antibodies
|
EP2032604A2
(en)
|
2006-06-06 |
2009-03-11 |
Genentech, Inc. |
Anti-dll4 antibodies and methods using same
|
CN1903880B
(zh)
*
|
2006-08-02 |
2010-05-12 |
中国人民解放军军事医学科学院基础医学研究所 |
抗肿瘤血管内皮生长因子vegf-e抗原及其编码基因与应用
|
DK2056874T3
(da)
|
2006-08-21 |
2012-10-15 |
Hoffmann La Roche |
Tumorterapi med et anti-vegf-antistof
|
CN101148474B
(zh)
*
|
2006-09-21 |
2014-06-11 |
上海杰隆生物工程股份有限公司 |
人源人血管内皮生长因子单克隆抗体及其制备方法
|
CA2671734A1
(en)
|
2006-12-19 |
2008-06-26 |
Genentech, Inc. |
Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
EP2158215B1
(en)
|
2007-05-17 |
2015-04-22 |
Genentech, Inc. |
Crystal structures of neuropilin fragments and neuropilin-antibody complexes
|
CA2687247A1
(en)
|
2007-05-17 |
2008-11-27 |
Genentech, Inc. |
Inhibition of tumor metastasis by anti neuropilin 2 antibodies
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
EP2840090B1
(en)
|
2007-10-30 |
2018-02-21 |
Genentech, Inc. |
Antibody purification by cation exchange chromatography
|
CN101918022A
(zh)
|
2007-11-09 |
2010-12-15 |
健泰科生物技术公司 |
激活蛋白受体样激酶-1组合物及使用方法
|
TWI580694B
(zh)
*
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
RU2531523C3
(ru)
*
|
2008-06-25 |
2022-05-04 |
Новартис Аг |
Стабильные и растворимые антитела, ингибирующие vegf
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
CN102245208B
(zh)
|
2008-10-14 |
2016-03-16 |
霍夫曼-拉罗奇有限公司 |
免疫球蛋白变体及其用途
|
WO2010060748A1
(en)
|
2008-11-03 |
2010-06-03 |
Molecular Partners Ag |
Binding proteins inhibiting the vegf-a receptor interaction
|
CA2744158A1
(en)
|
2008-11-22 |
2010-05-27 |
Genentech, Inc. |
Anti-angiogenesis therapy for the treatment of breast cancer
|
BRPI0918211A2
(pt)
|
2008-12-23 |
2015-12-08 |
Genentech Inc |
métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf
|
WO2010112193A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
JP2012522491A
(ja)
*
|
2009-04-03 |
2012-09-27 |
ベジニクス ピーティーワイ リミテッド |
抗vegf−d抗体
|
PL2417156T3
(pl)
|
2009-04-07 |
2015-07-31 |
Roche Glycart Ag |
Trójwartościowe, bispecyficzne przeciwciała
|
WO2010129609A2
(en)
|
2009-05-07 |
2010-11-11 |
The Regents Of The University Of California |
Antibodies and methods of use thereof
|
MX2011010570A
(es)
|
2009-05-08 |
2011-10-19 |
Genentech Inc |
Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos.
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
KR20120034739A
(ko)
|
2009-06-17 |
2012-04-12 |
애보트 바이오테라퓨틱스 코포레이션 |
항-vegf 항체 및 그의 용도
|
CN106148547A
(zh)
|
2009-07-13 |
2016-11-23 |
霍夫曼-拉罗奇有限公司 |
用于癌症治疗的诊断方法和组合物
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
EP2459591B1
(en)
|
2009-07-31 |
2014-08-20 |
Genentech, Inc. |
Inhibition of tumor metastasis using anti-g-csf-antibodies
|
BR112012003346A2
(pt)
|
2009-08-15 |
2016-11-16 |
Genentech Inc |
metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
|
US20110064670A1
(en)
|
2009-09-11 |
2011-03-17 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
CN102712696A
(zh)
|
2009-09-16 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
WO2011033006A1
(en)
|
2009-09-17 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
CN102051396B
(zh)
*
|
2009-11-04 |
2014-07-16 |
无锡天演生物技术有限公司 |
雁阵式定域随机突变方法及其在单抗分子进化技术中的应用
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗-vegf-c抗體及其使用方法
|
SG2014011340A
(en)
|
2009-12-21 |
2014-07-30 |
Genentech Inc |
Antibody formulation
|
MX2012007379A
(es)
|
2009-12-23 |
2012-08-31 |
Genentech Inc |
Anticuerpos anti-bv8 y usos de los mismos.
|
FR2955773B1
(fr)
|
2010-02-01 |
2017-05-26 |
Commissariat A L'energie Atomique |
Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
|
EP3696194A1
(en)
|
2010-02-23 |
2020-08-19 |
F. Hoffmann-La Roche AG |
Anti-angiogenesis therapy for the treatment of ovarian cancer
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
CN102863533B
(zh)
*
|
2010-06-21 |
2013-12-11 |
中国科学技术大学 |
抗体人源化改造方法
|
SG186983A1
(en)
|
2010-07-09 |
2013-02-28 |
Genentech Inc |
Anti-neuropilin antibodies and methods of use
|
EP2596361A1
(en)
|
2010-07-19 |
2013-05-29 |
F.Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
JP2013538338A
(ja)
|
2010-07-19 |
2013-10-10 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗癌治療への応答可能性の増大した患者を同定する方法
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
EA201390722A1
(ru)
|
2010-11-15 |
2013-11-29 |
Файв Прайм Терапьютикс, Инк. |
Лечение рака повышенными дозами растворимых белков слияния fgfr1
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
DK2658970T3
(en)
*
|
2010-12-31 |
2017-01-16 |
Bioatla Llc |
Express humanization of antibodies
|
BR112013020338A2
(pt)
|
2011-02-28 |
2016-10-18 |
Hoffmann La Roche |
proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
|
EP2681239B8
(en)
|
2011-02-28 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Antigen binding proteins
|
HUE041335T2
(hu)
|
2011-03-29 |
2019-05-28 |
Roche Glycart Ag |
Antitest FC-variánsok
|
US9346789B2
(en)
|
2011-04-01 |
2016-05-24 |
Genentech, Inc. |
Combinations of AKT inhibitor compounds and abiraterone, and methods of use
|
AU2012245439B2
(en)
|
2011-04-20 |
2017-04-06 |
Acceleron Pharma, Inc. |
Endoglin polypeptides and uses thereof
|
JP2014513128A
(ja)
|
2011-05-03 |
2014-05-29 |
ジェネンテック, インコーポレイテッド |
血管破壊剤とその使用
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
US9057728B2
(en)
|
2011-07-12 |
2015-06-16 |
Epitomics, Inc. |
FACS-based method for obtaining an antibody sequence
|
EP2744825A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Inhibition of angiogenesis in refractory tumors
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
BR112014019579A2
(pt)
|
2012-02-10 |
2019-10-15 |
Genentech, Inc |
Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
|
MX365139B
(es)
|
2012-03-13 |
2019-05-24 |
Hoffmann La Roche |
Uso de una terapia combinada de bevacizumab y paclitaxel en el tratamiento de cáncer de ovario epitelial resistente al platino, carcinoma de las trompas de falopio resistente al platino, o carcinoma peritoneal primario resistente al platino.
|
MY186099A
(en)
|
2012-05-31 |
2021-06-22 |
Genentech Inc |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
BR112014032193A2
(pt)
|
2012-06-27 |
2017-06-27 |
Hoffmann La Roche |
métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
LT2872534T
(lt)
|
2012-07-13 |
2018-10-25 |
Roche Glycart Ag |
Dvigubai specifiniai anti-vegf/anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
|
MX360189B
(es)
|
2012-08-07 |
2018-10-24 |
Genentech Inc |
Terapia de combinacion para el tratamiento de glioblastoma.
|
EP2916835A4
(en)
|
2012-11-12 |
2016-07-27 |
Redwood Bioscience Inc |
COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
WO2014078733A1
(en)
|
2012-11-16 |
2014-05-22 |
The Regents Of The University Of California |
Pictet-spengler ligation for protein chemical modification
|
FR2998579B1
(fr)
|
2012-11-27 |
2015-06-19 |
Commissariat Energie Atomique |
Methode pour obtenir des anticorps humains specifiques d'un antigene par immunisation in vitro
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
MY189047A
(en)
|
2013-03-13 |
2022-01-21 |
Genentech Inc |
Antibody formulations
|
KR20150131208A
(ko)
|
2013-03-13 |
2015-11-24 |
이미지냅 인코포레이티드 |
Cd8에의 항원 결합 구조체들
|
US9775881B2
(en)
|
2013-05-23 |
2017-10-03 |
Five Prime Therapeutics, Inc. |
Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
WO2015061666A1
(en)
|
2013-10-25 |
2015-04-30 |
Acceleron Pharma, Inc. |
Endoglin peptides to treat fibrotic diseases
|
US10568951B2
(en)
|
2013-11-18 |
2020-02-25 |
Formycon Ag |
Pharmaceutical composition of an anti-VEGF antibody
|
US9493413B2
(en)
|
2013-11-27 |
2016-11-15 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
SG11201604738TA
(en)
*
|
2013-12-12 |
2016-07-28 |
Shanghai Hengrui Pharm Co Ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
PT3083680T
(pt)
|
2013-12-20 |
2020-03-17 |
Hoffmann La Roche |
Anticorpos humanizados anti-tau(ps422) e métodos de utilização
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
MA39776A
(fr)
|
2014-03-24 |
2017-02-01 |
Hoffmann La Roche |
Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
|
MA39817A
(fr)
|
2014-03-31 |
2017-02-08 |
Hoffmann La Roche |
Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
|
EP3143044A1
(en)
|
2014-05-12 |
2017-03-22 |
Formycon AG |
Pre-filled plastic syringe containing a vegf antagonist
|
EP3151830A4
(en)
|
2014-06-06 |
2018-02-07 |
Redwood Bioscience, Inc. |
Anti-her2 antibody-maytansine conjugates and methods of use thereof
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
EP3169801A1
(en)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for treatment of glioblastoma
|
EP3646879B1
(en)
|
2014-08-12 |
2024-04-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with integrin-binding-fc-fusion protein and an immune checkpoint inhibitor
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
MX2017003227A
(es)
|
2014-09-13 |
2017-12-04 |
Novartis Ag |
Terapias de combinacion de inhibidores de alk.
|
EP3193932B1
(en)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
ES2774448T3
(es)
|
2014-10-03 |
2020-07-21 |
Novartis Ag |
Terapias de combinación
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
CA2959821A1
(en)
|
2014-10-24 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
JP6929771B2
(ja)
|
2014-11-10 |
2021-09-01 |
ジェネンテック, インコーポレイテッド |
抗インターロイキン−33抗体及びその使用
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
WO2016106340A2
(en)
|
2014-12-23 |
2016-06-30 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
US9862763B2
(en)
*
|
2015-06-24 |
2018-01-09 |
Hoffmann-La Roche Inc. |
Humanized anti-tau(pS422) antibodies and methods of use
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
SI3317301T1
(sl)
|
2015-07-29 |
2021-10-29 |
Novartis Ag |
Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
|
AU2016304764C1
(en)
|
2015-08-07 |
2023-06-01 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
PE20181009A1
(es)
|
2015-10-30 |
2018-06-26 |
Genentech Inc |
ANTICUERPOS ANTI-HtrA1 Y METODOS DE USO DE LOS MISMOS
|
CN108473584B
(zh)
|
2015-11-03 |
2022-01-14 |
詹森生物科技公司 |
特异性结合pd-1和tim-3的抗体及其用途
|
EP3370764A4
(en)
|
2015-11-05 |
2019-07-17 |
The Regents of The University of California |
CELLS MARKED BY LIPID CONJUGATES AND METHODS OF USING THE SAME
|
WO2017087798A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
CA3005692A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
AU2016356717B2
(en)
|
2015-11-18 |
2022-09-29 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
KR20180088907A
(ko)
|
2015-12-17 |
2018-08-07 |
노파르티스 아게 |
Pd-1에 대한 항체 분자 및 그의 용도
|
RU2744860C2
(ru)
|
2015-12-30 |
2021-03-16 |
Кодиак Сайенсиз Инк. |
Антитела и их конъюгаты
|
WO2017129685A1
(en)
|
2016-01-26 |
2017-08-03 |
Formycon Ag |
Liquid formulation of a vegf antagonist
|
CN105481981B
(zh)
*
|
2016-01-27 |
2019-03-19 |
中国人民解放军第二军医大学 |
靶向vegf双特异性抗体及其用途
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
CN109154613A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
EP3482205A1
(en)
|
2016-07-08 |
2019-05-15 |
H. Hoffnabb-La Roche Ag |
Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
|
WO2018009939A1
(en)
|
2016-07-08 |
2018-01-11 |
Genentech, Inc. |
Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
|
BR112019002036A2
(pt)
|
2016-08-12 |
2019-05-14 |
Genentech Inc |
métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal
|
ES2836286T3
(es)
*
|
2016-08-23 |
2021-06-24 |
Medimmune Ltd |
Anticuerpos anti-VEGF-A y usos de los mismos
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
AU2018207303A1
(en)
|
2017-01-10 |
2019-07-25 |
xCella Biosciences, Inc. |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
|
EP3589754B1
(en)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
CA3063995A1
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
US11312783B2
(en)
|
2017-06-22 |
2022-04-26 |
Novartis Ag |
Antibody molecules to CD73 and uses thereof
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
WO2019129679A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
EP3762421A2
(en)
|
2018-03-09 |
2021-01-13 |
Agenus Inc. |
Anti-cd73 antibodies and methods of use thereof
|
CN113975264A
(zh)
|
2018-04-16 |
2022-01-28 |
上海岸阔医药科技有限公司 |
预防或治疗肿瘤疗法副作用的方法
|
BR112020023872A2
(pt)
|
2018-05-24 |
2021-02-17 |
Janssen Biotech, Inc. |
agentes de ligação de psma e seus usos
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
US20220185875A1
(en)
|
2019-03-18 |
2022-06-16 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bispecific antibody specifically bound to vegf and ang2
|
CA3136888A1
(en)
|
2019-04-19 |
2020-10-22 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti- psma/cd3 antibody
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
WO2020227554A1
(en)
*
|
2019-05-09 |
2020-11-12 |
Genentech, Inc. |
Methods of making antibodies
|
US11661454B2
(en)
|
2019-08-09 |
2023-05-30 |
Anhui Biox Vision Biological Technology Co., Ltd. |
Anti-VEGF-PD1 bispecific antibody with novel structure and use thereof
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
CR20220461A
(es)
|
2020-03-13 |
2022-10-21 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos
|
CN113461824A
(zh)
|
2020-03-31 |
2021-10-01 |
普米斯生物技术(珠海)有限公司 |
一种构建多特异性抗体的平台
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
FR3110838B1
(fr)
|
2020-05-28 |
2022-06-24 |
Commissariat Energie Atomique |
Complexe immunomodulateur et ses applications pour la thérapie
|
AU2021302958A1
(en)
|
2020-06-30 |
2023-02-16 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
CN114106190A
(zh)
|
2020-08-31 |
2022-03-01 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
CA3201521A1
(en)
|
2020-11-13 |
2022-05-19 |
Genentech, Inc. |
Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
|
JP2024506249A
(ja)
|
2021-01-22 |
2024-02-13 |
メンドゥス・ベスローテン・フェンノートシャップ |
腫瘍ワクチン接種の方法
|
WO2022162518A2
(en)
|
2021-01-28 |
2022-08-04 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
WO2022232503A1
(en)
|
2021-04-30 |
2022-11-03 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
WO2023010095A1
(en)
|
2021-07-28 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
WO2024062072A2
(en)
|
2022-09-21 |
2024-03-28 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
WO2024062082A1
(en)
|
2022-09-21 |
2024-03-28 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
WO2024062076A1
(en)
|
2022-09-21 |
2024-03-28 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|